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ABSTRACT
Background: Hepatitis C virus (HCV) effectively estab-
lishes persistent infection in human livers. The non-
structural (NS) 3/4A complex participates in this process
by cleavage of interferon b (IFNb) promoter stimulator-1
(IPS-1; also termed Cardif/MAVS/VISA), which inhibits
responses to double stranded (ds) RNA. However, it is not
known whether this effect extends beyond innate
responses.
Aims: To test if HCV NS3/4A affects innate and adaptive
immune responses in vivo.
Methods: NS3 levels were semi-quantified in human liver
biopsies, transfected cells, and in transgenic (Tg) mouse
livers by western blot. The effect of NS3/4A on dsRNA-
mediated signalling and on the integrity of IPS-1 was
analysed using in vitro translation, transfected cells and
Tg mice. Cytotoxic T cell (CTL)-mediated clearance of
transient firefly luciferase (FLuc)- and/or NS3/4A-Tg
hepatocytes was determined using in vivo imaging and
western blot.
Results: NS3 protein levels were in a comparable range
(0.1–49 mg/gtissue)ininfectedhumanlivers andTgmouse
livers. Importantly, these levels of NS3/4A reduced murine
innate responses to synthetic dsRNA in vivo, supporting the
possibility that this occurs also in infected humans. The
likely explanation for this was the NS3/4A-mediated
cleavage of mouse IPS-1, albeit less efficiently than human
IPS-1. Despite this, FLuc- and/or NS3/4A-expressing murine
hepatocytes were effectively eliminated by hepatic CTLs,
utilising the classical molecules for virus-infected cell lysis,
including CD8, IFNc, perforin and FasL.
Conclusions: Although HCV NS3/4A inhibits the innate
immunity, this does not prevent CTL-mediated clearance
of NS3/4A-expressing hepatocytes in vivo. Thus, other
HCV proteins are most likely responsible for interfering
with the adaptive immunity.
Hepatitis C virus (HCV) is highly efficient in
establishing persistent infections in human hepa-
tocytes in vivo, but not in vitro.
12Several HCV
proteins protect infected cells against the various
ways that the host can shut down or eliminate
infected cells
3 and the specific T cell responses seem
to be deregulated during chronic infection.
4–10 This
impairment may be caused by escape mutations
within T cell epitopes
11–14 or by an inhibitory effect
directly exerted by viral proteins.
4 Indeed, trans-
genic (Tg) mice expressing the complete HCV
polyprotein have an impaired clearance of hepato-
tropic infections,
15 but the protein/s responsible has/
have yet not been identified. Examples of events
documented in transgenic mice are inhibition of
Fas-mediated apoptosis, reduced sensitivity to
tumour necrosis factor a (TNFa)-mediated apopto-
sis, and reduced interferon (IFN) responses.
15–17
However, these studies are hampered in that we
do not know whether similar effects can be observed
in both human and murine cells.
HCV infection itself does not seem to be highly
immunogenic.
18 Certain HCV proteins, in particu-
lar the non-structural (NS) 3/4A complex, have
been found to modulate the host response.
3 The
NS3/4A protease has been shown to cleave adaptor
proteins transducing the host cell response to the
double stranded (ds) RNA generated during repli-
cation of the viral genome.
19 20 HCV dsRNA is
synthesised by the membrane-bound replication
complex in the endoplasmic reticulum and lipid
droplets
21 can activate the retinoic acid-inducible
gene-I (RIG-I) pathway. The RIG-I pathway
activates nuclear factor kB (NF-kB) and IFN
responses, which switches the cell into an antiviral
state.
32 2 However, to prevent this response, the
protease domain of the HCV NS3/4A complex
cleaves the IFNb promoter stimulator-1 (IPS-1; also
known as caspase recruitment domain adaptor
inducing IFNb (Cardif), mitochondrial anti-viral
signalling protein (MAVS) and virus-induced sig-
nalling adaptor (VISA)) signal transducer from the
mitochondria. This prevents nuclear translocation
of transcription factors interferon regulatory factor
3 (IRF-3) and NF-kB,
23 and inhibits IFN responses
and apoptosis. However, most of these results have
been generated from transfected tumour cells in
vitro, and less is known about any in vivo
consequences.
31 92 3New data obtained using unre-
lated RNA viruses suggest that IPS-1 does not
influence adaptive immune responses.
24 25 Hence,
although it is clear that the NS3/4A protein in vitro
inhibits innate signalling through IPS-1, it is not
known if this affects the adaptive immune
responses.
To better understand the in vivo role of NS3/4A-
mediated inhibition of innate responses seen in
human tumour cells transfected by HCV NS3/4A,
we aimed to determine whether effects similar to
those reported could be observed in murine cells.
This is certainly of importance since this would
allow detailed in vivo studies in Tg mice that
mimic events taking place in the human liver.
MATERIALS AND METHODS
Human liver biopsies
Liver biopsies were taken from six patients under-
going clinical routine work-up using an aspirating
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snap-frozen in liquid nitrogen. Five patients had confirmed
chronic HCV infections with a viral load of 14.2610
6 (male,
gt1), 8.8610
6 (male, gt3a), 0.45610
6 (male, gt3a) and
0.44610
6 IU/ml (female, gt1a). For one male patient infected
by HCV gt1 the viral load had not been determined. All HCV-
infected patients had inflammation ranging from grade I to
grade III and fibrosis ranging from grade I to grade IV. A patient
with a liver disease not caused by HCV was used as a negative
control and had minimal inflammation and intermediate
steatosis.
Animals
Inbred C57BL/6 (H-2
b), BALB/c (H-2
d) (Charles River, Sulzfeld,
Germany), Perforin2/2 (H-2
b), FasL2/2 (H-2
b) (The Jackson
Laboratory, Bar Harbor, Maine, USA), CD42/2 (H-2
b), CD82/
2 (H-2
b), TLR42/2 (H-2
b) and IFNcR22/2 (H-2
b) 4–8-week-
old mice were obtained from the breeding facility at the
Department of Microbiology, Tumor and Cell Biology,
Karolinska Institutet, Sweden. C57BL/6 and CBAxC57BL/6 Tg
mice with intra-hepatic expression of the NS3/4A proteins
17
were bred and maintained in-house.
Plasmid DNA, recombinant protein and synthetic peptides
Plasmids containing a full-length wild-type (wt) NS3, wtNS3/
4A, mutant (mut) NS3/4A with a mutation that prevents
cleavage between NS3 and NS4A, three alanine mutant NS3/4A
genes where the cleavage of NS3-NS4A was retained,
13 14 and a
codon optimised (co) NS3/4A gene in pVAX1 have been
described.
26–28 Genes coding for FLuc2- (Promega, Madison,
Wisconsin, USA) and human (h) and mouse (m) IPS-1
(InvivoGen) were separately cloned into pVAX1 using standard
techniques. The pISRE-TA-Luc and pRL-TA-Luc plasmids were
purchased from Promega.
Recombinant NS3 (rNS3) protein has been described.
17 The
NS3-derived major histocompatibility complex (MHC) class I
H-2D
b-restricted GAVQNEVTL peptide and the HBc-derived H-
2K
b-restricted MGLKFRQL peptide were kindly provided by Dr
Michael Levi, Tripep AB, Stockholm, Sweden.
17 Peptides were
synthesised using standard protocols with 9-fluorenylmethox-
ycarbonyl to protect the amino acids.
29
Cell lines
The SP2/0-Ag14 (H-2
d), RMA-S cells (kindly provided by
Professor K Ka ¨rre, Karolinska Institutet, Sweden), HepG2, and
Figure 1 Inhibition of interferon (IFN)
responses to dsRNA in human cells (A)
determined by firefly luciferase (FLuc)
expression in cell lysates of HEK293 cells
36 h after co-transfection with pISRE-Luc
reporter plasmid and indicated NS3- and
NS3/4A-containing plasmids. Mean
values were compared using the Student
t test. The effect of NS3 and NS3/4A on
poly(I:C)-induced nuclear factor kappaB
(NF-kB) in transiently transfected SP2/0
(H-2
d) cells (B). The ‘‘+’’ indicates cells
co-transfected with poly(I:C), ‘‘(+)’’
indicates cells treated with poly(I:C) 5 h
post-transfection. Detection of NS3
protein in human liver biopsies (5 mg) by
immunoprecipitation and western blot
analysis (C). ‘‘M’’ indicates the molecular
rainbow marker, ‘‘Pos ctrl’’ NS3/4A
transiently transfected HepG2 cells, ‘‘Neg
ctrl’’ is a wild-type mouse liver (C). Semi-
quantification of NS3-protein expression
(mg/g liver tissue) in human livers, stable
and transiently NS3/4A-transgenic mouse
livers (D). All experiments were run at
least three times, except for 1(D), which
is a summary of data from several
experiments. HCV, hepatitis C virus;
ISRE, interferon stimulatory response
element.
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17 SP2/0-Ag14 cells with
stable expression of NS3/4A
23 were maintained with 800 mg/ml
geneticin.
Transient transfection and protein sample preparation
HepG2 and SP2/0 cells were transiently transfected as
described.
23 In brief, the cells were plated into 10 cm
2 wells
(5610
6 cells/well) the day before transfection. Two micrograms
of each pVAX1 plasmid was transfected into cells using
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, California,
USA). Cells were either co-transfected using 0.2–2 mg/ml
poly(I:C) or treated with 0.2–2 mg/ml poly(I:C) 5 h after
transfection or left untreated. After transfection, the cells were
incubated for 16–36 h at 37uC, 5% CO2 prior to harvest and
subsequent isolation of cytoplasmic and nuclear protein
fractions, according to standard protocols. In brief, cells were
re-suspended in lysis buffer (10 mmol/l HEPES–KOH,
1.5 mmol/l MgCl2, 10 mmol/l KCl, 0.2 mmol/l phenylmetha-
nesulfonyl fluoride (PMSF), 1 mmol/l Na3VO4 and 0.5 mmol/l
dithiothreitol (DTT)), sonicated and incubated on ice for
10 min. Then the samples were centrifuged and the supernatant
containing the cytoplasmic portion was collected. The remain-
ing cell pellet was re-suspended in a different lysis buffer
(20 mmol/l HEPES–KOH, 1.5 mmol/l MgCl2, 420 mmol/l KCl,
0.2 mmol/l EDTA, 25% glycerol, 0.2 mmol/l PMSF, 1 mmol/l
Na3VO4 and 0.5 mmol/l DTT) and incubated for 30 min on ice
before the nuclear portion was collected by centrifugation. All
protein extracts were stored at 280uC until analysis.
Detection of IRF-3, NF-kB and IPS-1 by western blot
Cytoplasmic and nuclear extracts from transiently transfected
cells were loaded on a 4–12% Tris–Bis gel (Invitrogen) for
analysis by using sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS–PAGE). Proteins were transferred to an
Figure 2 NS3/4A-protein expression in mice disturbs responses to synthetic dsRNA. The nuclear translocation of interferon regulatory factor 3 (IRF-3)
and nuclear factor kB (NF-kB) by intravenous poly(I:C) is reduced in stable NS3/4A-Tg mice (A), but not by tumour necrosis factor a (TNFa)/D-GalN
treatment (B), representing a retinoic acid inducible gene-I (RIG-I)-independent pathway. Cleavage of murine (m) interferon b (IFNb) promoter
stimulator-1 (IPS-1) by the NS3/4A protease was determined using a standard in vitro transcription and translation assay in presence of
35S-methionine
and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) (C). The loading of each lane is indicated under the gel. Expression of
mIPS-1 alone generates a single protein band, whereas mIPS-1 co-expressed with wtNS3/4A or coNS3/4A, but not wtNS3 (data not shown), generates
two distinct protein bands, one representing mIPS-1 and the other the truncated mIPS-1 (C). Detection of cleaved hIPS-1 (DhIPS-1) and DmIPS-1 in
HepG2 cells (D) co-transfected with human (upper gel) or mouse (lower gel) IPS-1 by HCV NS3/4A and appropriate controls. Uncleaved IPS-1 generates
one single band in the western blot analysis. In the presence of a functional NS3/4A protease (wtNS3/4A and coNS3/4A) a cleavage of IPS-1 generates
two distinct bands on the membrane. mNS3/4A has a mutation that prevents the release of NS4A and the generation of the complete NS3/4A complex
(D). Comparison of the efficiency of human IPS-1 cleavage by the NS3/4A sequence with alanine mutations at residues 111, 112 or 113 of the NS3
protease with the cleavage of murine IPS-1 (E). Also shown is a parallel analysis of the cleavage of mouse IPS-1 by HBcAg (negative control), wild-type
NS3, mutant NS3/4A with an impaired protease, and coNS3/4A with a functional protease. All experiments shown have been repeated two to five times.
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(Invitrogen) for 1 h at 30 V. For detection of IRF-3, NF-kB
and IPS-1, a rabbit-IRF-3 antibody (#4962; Cell Signaling,
Danvers, Massachusetts, USA), a rabbit-NF-kB p65 antibody
(#3034; Cell Signaling) or a rabbit-IPS-1 antibody (AT107;
Alexis Biochemicals, San Diego, California, USA) was used at a
dilution of 1:1000, 1:1000 and 1:2000, respectively. Bound
antibody was detected using an enzyme conjugated goat-anti-
rabbit antibody (Dako, Glostrup, Denmark), and proteins were
visualised using the ECL Plus western blotting reagent (GE
Healthcare, Uppsala, Sweden) according to manufacturer’s
protocol.
Luciferase reporter assay
A reporter plasmid containing the interferon stimulatory
response element (ISRE) enhancer upstream of the TATA box
and luciferase (Clontech, Mountain View, California, USA)
were used for transient transfections of HEK293 cells. For
transfections, 10
5 cells were plated per well in a 24-well plate
before co-transfected with 0.125 mg of pISRE-TA-Luc (firefly)
reporter plasmid, 0.01 mg of pRL-TK (Renilla) reporter plasmid
and 0.375 mg empty pVAX1 plasmid or pVAX1 plasmid
containing wtNS3, wtNS3/4A or coNS3/4A using the
Lipofectamine 2000 reagent (Invitrogen). At 16 h post-transfec-
tion the cells were treated with 2 mg/ml poly(I:C). Cell lysates
collected 6–24 h after poly(I:C) treatment were analysed for
luciferase activity using the dual-luciferase reporter assay
system (Promega) according to the manufacturer’s protocol.
Light emission was detected in an Anthos Lucy2 luminometer
and was analysed using the Anthos LucySoft software (Anthos
Labtech Instruments, Vienna, Austria) and Microsoft Excel.
In vitro transcription and translation assay
The cleavage of mIPS-1 was analysed by co-expression of 1 mg
mIPS-1 and 1 mg wtNS3, wtNS3/4A or coNS3/4A DNA
plasmids by an in vitro transcription and translation assay
(TNT; Promega), as described.
14 26
Immunisation and treatment protocols
DNA immunisations were performed by regular intramuscular
(i.m.) immunisation in the tibialis anterior muscle (50 mg/dose)
or by gene gun-based immunisation (2 mg/dose) exactly as
described previously.
26 27
The effects of synthetic dsRNA in vivo was studied by
injecting 100 mg poly(I:C) (Invitrogen) in 200 ml sterile phos-
phate-buffered saline (PBS) or 200 ml sterile PBS alone intrave-
nously into the tail vein. The effect of TNFa was studied after
i.p. injection of TNFa at doses of 5–20 mg/kg with D-
galactosamine (D-GalN) (20 mg) in 100 ml PBS as previously
described.
17
Determination of HCV NS3/4A-protein-expressing liver cells in
vivo
NS3 protein expression was determined in human (5 mg) and
murine (100 mg) livers as described.
26 27 30 Groups of mice were
immunised once using the gene gun or left untreated. Two
weeks later the mice were given a hydrodynamic injection of the
coNS3/4A plasmid, exactly as described previously.
30 31 The
presence of NS3/4A-protein expression was determined 72 h
later by immuno-precipitation and western blot as described
previously.
26 27 30
For in vivo imaging, groups of mice were immunised once
intramuscularly in the right tibialis anterior muscle with either
50 mg of Luc2-pVAX1 plasmid, 50 mg of the coNS3/4A plasmid,
or left untreated. Two weeks later the mice were given a
hydrodynamic injection containing 50 mg Luc2 and 50 mg
coNS3/4A plasmid. The presence of reporter gene expression
was determined from 7 h to 192 h by bioluminescence in
anaesthetised mice using the In Vivo Imaging System 100 (IVIS
100, Xenogen, Hopkinton, Massachusetts, USA). To detect the
presence of reporter gene expression the luciferin (Xenogen)
substrate was injected and the reporter gene expression was
analysed 5–10 min later for 1.5 and/or 60 s (depending on time
point). Images and assessment of emitted light were analysed
with Living Image software (version 2.50; Xenogen).
Detection of NS3/4A-specific lytic CTLs, IFNc-producing CTLs
and T helper cells, and intra-hepatic T cells
Lytic cytotoxic T cells (CTLs) in immunised mice were detected
in individual mouse spleens by a standard 4-h
51Cr-release assay
using NS3 peptide (GAVQNEVTL) loaded H-2D
b-expressing
RMA-S target cells exactly as described previously.
30 The
presence of IFNc-producing CTLs and T helper (Th) cells to
NS3 was detected in pooled splenocyte cultures by a commer-
cially available ELISpot assay as described previously.
13 30
The detection of CD3+ T cells in the liver was performed by
immunohistochemistry as described previously.
30 The mean
values of staining scores and standard deviations were
calculated for vaccinated and non-vaccinated animals and
compared using the Mann–Whitney U test.
Statistical analysis
Statistical comparisons were performed using the Statview 5.0
(3/20/98, Power PC version, SAS Institute) and Excel:mac
(version 11.3.7, Microsoft) software packages for Macintosh.
Parametrical data were compared using the Student t test
(Statview and Excel) and non-parametric data were compared
using the Mann–Whitney U test (Statview). Frequencies were
compared using Fisher’s exact test (Statview).
RESULTS
HCV NS3/4A gt1a interferes with IFN signalling and NF-kB
activation in human and murine tumour cells
Interference of our gt 1a NS3/4A sequence with IFN responses
was tested in human HEK-293 cells co-transfected with NS3
and a reporter plasmid controlled by an IFN-sensitive promoter.
This revealed that synthetic dsRNA, ie, poly(I:C)-induced IFN
reporter expression, was impaired by the NS3/4A genes (fig 1A).
Also, the coNS3/4A gene reduced NF-kB activation in tran-
siently transfected poly(I:C)-treated HepG2 cells (data not
shown). Thus, our gt1a NS3/4A gene behaves the same way as
other NS3/4A sequences.
19 32
We next tested if NS3/4A had similar effects in murine
tumour cells. First, the basal level of NF-kB was reduced in SP2/
0 cells stably expressing the NS3/4A-proteins (data not shown),
and in transiently NS3/4A-transfected poly(I:C)-stimulated
SP2/0 cells (fig 1B). No difference in MHC class I expression
was seen between non-transfected and NS3/4A-transfected
SP2/0 cells (data not shown). Collectively, NS3/4A affects NF-
kB responses in murine tumour cells, but not class I antigen
presentation.
Expression levels of NS3-protein in human and murine livers
To explore the effects of NS3/4A on non-tumour cells in vivo,
we used our different NS3/4A-Tg mouse models.
17 30 We first
compared the levels of NS3 expression between human HCV
Hepatology
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were estimated using a standard curve obtained with dilutions
of recombinant NS3 (fig 1D). In liver biopsies from two patients
with high viral load (.800 000 IU/ml serum) the levels of NS3
were 45 (gt1a) and 41 mg/g (gt3a) tissue, respectively (fig 1C,
lanes 2 and 4, respectively). In another two patients, each with
an intermediate viral load (450 000 and 550 000 IU/ml,
respectively), the NS3 levels were 31 and 15 mg/g tissue,
respectively (fig 1D). From one patient with an unknown viral
load the NS3 levels were 49 mg/g liver tissue (fig 1D). The
average NS3 expression levels in five human livers were 36 (SD
14) mg/g tissue. An analysis of the NS3 levels in stable Tg (sTg)
mice ranged from 0.1 to 0.5 mg in females (n=7; mean 0.3 (SD
0.2) mg/g) and from 0.2 to 4 in males (n=42; mean 1.5 (SD
3.7) mg/g), consistent with previous observations.
17 In the
transiently Tg (tTg) mice (n=6) the levels ranged from 0.5 to
11 mg/g tissue, with a mean of 4 (SD 4) mg/g tissue. Taken
together, this suggests that the mean levels of NS3 in the male
stable NS3/4A-Tg mice were on average 22-fold lower as
compared to four patients with a viral load exceeding
400 000 IU/ml. In contrast, the NS3 levels in livers from the
transient Tg mice were more within the same range as the
tested human livers, on average 8-fold lower, and may possibly
even exceed those in patients with a lower viral load. Thus, the
NS3 levels seem to be lower in the stable Tg mice as compared
to humans with a viral load exceeding 400 000 IU/ml, whereas
the NS3 levels in the transiently Tg mice are more comparable
to humans. Finally, a larger study on NS3 expression in human
livers is under way, and we have not seen a band corresponding
to NS3 in any of more than 20 patients negative for HCV
infection (Rahbin et al, manuscript in preparation). Also, we
have never seen a band corresponding to NS3 in a non-
transgenic mouse liver. Thus, the specificity of the currently
used western blot assay seems be satisfactory.
The role of NS3/4A on in vivo responses to dsRNA
We wanted to emulate the effects of an infection with an RNA
virus without activating the specific immune response, since
this would complicate analysis of innate responses in vivo. We
therefore used synthetic dsRNA, or poly(I:C), which only
activates the innate responses. After intravenous injection of
poly(I:C) the nuclear translocation of IRF-3 and NF-kB by the
RIG-I/TLR3-dependent pathway was determined (fig 2A). As a
comparison, the NS3/4A-Tg mice were also treated with TNFa/
D-GalN (fig 2B), representing a RIG-I/TLR3-independent path-
way.
33 A reduced nuclear translocation of IRF-3 and NF-kB in
the NS3/4A-Tg mice showed that the response to dsRNA was
impaired in vivo (fig 2A). In contrast, treatment with TNFa/D-
GalN had no effect on IRF-3 (fig 2B), whereas the NF-kB levels
were increased in the NS3/4A-Tg mice (fig 2B). The latter is
now a well-documented finding in these mice (Weiland et al,
manuscript in preparation). Thus, expression of NS3/4A in
mouse livers, at around 25-fold lower levels as compared to
those seen in HCV infected humans, specifically inhibits the
RIG-I/TLR3-dependent activation of IRF-3 and NF-kBb y
dsRNA. Thus, NS3/4A modulates the innate murine response
to dsRNA in vivo.
NS3/4A cleaves human and murine IPS-1
The best-documented effects of NS3/4A on cell signalling is the
cleavage of human IPS-1 from the mitochondrial mem-
brane.
19 23 34 Whether the same is true for IPS-1 of other species,
except for tamarins,
35 is not known. We first tested the cleavage
of murine IPS-1 by an in vitro transcription and translation
assay (fig 2C). Co-translation of mIPS-1 with NS3/4A results in
a reduction of free NS3, and the appearance of a band consistent
with truncated (D) IPS-1 (fig 2C and data not shown). Hence,
the cleavage of murine IPS-1 is competing with the cleavage at
the NS3–NS4A junction resulting in a reduction of free NS3.
This was confirmed by over-expressing human and murine IPS-
1 in HepG2 cells, where co-transfection with NS3/4A resulted in
an extra band representing DIPS-1 (fig 2D). Thus, HCV NS3/4A
cleaves both human and murine IPS-1. The exact position for
cleavage of murine IPS-1 is under investigation, although the
predicted site at the cysteine residue at position 470 of the
mouse IPS-1 should be a good candidate.
35 To better characterise
the difference in the effectiveness of cleavage of the human and
mouse IPS-1 we co-transfected HepG2 cells with versions of our
Figure 3 The non-structural (NS) 3/4A complex does not promote survival of firefly luciferase (FLuc) expression in co-transfected hepatocytes in vivo.
Real-time in vivo imaging of FLuc expression in mice 12, 36 and 336 h after a hydrodynamic injection of FLuc alone or in combination with coNS3/4A
(A) NS3/4A does not prevent clearance of NS3/4A-FLuc co-transfected hepatocytes in mice intramuscularly immunised with phosphate-buffered saline
(PBS), coNS3/4A-pVAX1 or FLuc-pVAX1 2 weeks prior to hydrodynamic injection (B). (See p 565 for panel B.) The presence of a statistical difference
has been indicated as follows: *p,0.05; **p,0.01, Mann–Whitney U test. The area used for calculation of light intensities has been boxed. All
experiments shown have been repeated at least thrice.
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tions and with intact protease activity.
13 14 Using these mutant
NS3/4A sequences we did see differences in the efficiency of
cleaving of the human IPS-1 gene (fig 2E), suggesting that the
generally fainter DmIPS-1 band observed is a result of a less
efficient cleavages as compared to human IPS-1 (fig 2E).
NS3/4A does not protect transiently transfected hepatocytes, as
a model of infected hepatocytes, from elimination by specific T
cells
Since NS3/4A inhibits the innate murine immune response, an
immediate question is whether this also has any clear effects on
the adaptive hepatic immune responses. We therefore used in
vivo imaging to study the real-time kinetics of clearance of
hepatocytes co-expressing NS3/4A and FLuc generated by a
hydrodynamic injection. Co-expression of NS3/4A did not
promote survival of FLuc-expressing cells in naive mice, where
hepatocytes co-expressing NS3/4A and FLuc persisted for fewer
than 14 days (336 h; fig 3A) but more than 8 days (192 h;
fig 3B). In contrast, mice with pre-existing NS3/4A-specific
CTLs had cleared most NS3/4A-FLuc co-expressing hepatocytes
between 24 and 48 h (fig 3B). Collectively, NS3/4A cannot
protect transfected, or ‘‘infected’’, hepatocytes from clearance
by specific T cells. This is consistent with the idea that IPS-1
does not have a major influence on the adaptive immunity.
24 25
Clearance of NS3/4A-expressing hepatocytes is dependent on
classical molecules involved in the killing of virus-infected cells
To define molecules involved in the effector-mediated clearance
of NS3/4A-protein expressing hepatocytes, we studied hepatic
Figure 3 continued.
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expression in vaccinated gene deficient ‘‘knock-out’’ mice. The
role of the molecules was defined by a hydrodynamic challenge
with an NS3/4A-expressing plasmid,
30 in naive or vaccinated
mice lacking specific genes involved in T cell priming or effector
function (CD4 and CD8), T cell trafficking (TLR4 and IFNc
receptor-2),
36 and lytic killing of virally infected cells (perforin
and FasL).
37 38
In wild-type mice, an NS3/4A-DNA vaccination activates
IFNc-producing Th cells and CTLs, and the CTLs have lytic
activity in vitro (fig 4A). These T cells enter the liver, evidenced
by an increase in hepatic CD3+ cells, and are functional, since
transiently NS3/4A-transgenic hepatocytes are cleared within
72 h (fig 4A). Consistent with previous reports,
26 30 were CD8+,
but not CD4+ cells required for clearance (fig 4B,C). CD42/2,
but not CD82/2 mice developed lytic and IFNc-producing T
cells that entered the liver and eliminated NS3/4A-protein
expressing hepatocytes (fig 4B,C). This is consistent with our
previous observation that priming and clearance of NS3/4A-
specific CTLs is independent of CD4+ cells, but dependent on
CD8+ T cells.
26 30
Next, IFNcR2, but not TLR4, was required for clearance of
NS3/4A-protein expressing hepatocytes (fig 4D,E), even though
the IFNcR22/2 mice had a strong lytic activity in vitro (fig 4E).
This may possibly be explained by the fact that the CTLs failed
to enter the liver (fig 4E), consistent with recent data showing
that IFNc is involved in trafficking of T cells to infected sites.
36
However, we found no role for TLR4 in either priming or
hepatic recruitment of newly primed NS3/4A-specific CTLs
(fig 4D), which is different from the suggested role of TLR4 in
trapping memory cells in the liver.
39
Lastly, hepatic clearance of NS3/4A-protein-expressing cells
was dependent on classical molecules involved in killing of
virally infected cells. Mice lacking perforin or FasL had a
significantly impaired clearance of hepatic NS3/4A-protein
expression (fig 4F,G), strongly suggesting that these molecules
Figure 4 Presence of non-structural (NS)3-specific interferon c (IFNc)-producing spot forming cells (SFCs) by ELISpot (bar graphs), lytic cytoxic T
cells (CTLs; line graphs), and hepatic NS3 (gels) in vaccinated and non-vaccinated mice receiving a hydrodynamic challenge. SFCs were counted after
stimulation with a H-2D
b restricted major histocompatibility complex (MHC) class I peptide (GAVQNEVTL), recombinant (r) NS3, or an irrelevant MHC
class I peptide (HBc) in pooled lymph nodes from naive or gene-gun immunised wild-type (A), CD42/2 (B), CD82/2 (C), TLR42/2 (D), IFNcR22/2
(E), perforin2/2 (F) and FasL2/2 (G) mice. (See p 567 for panels E to G.) A cut-off at 50 SFCs/10
6 cells indicates a positive IFNc response. NS3-
specific lytic CTL activity using peptide was determined using peptide-loaded RMA-S cells in splenocytes from individual mice, re-stimulated in the
presence of the H-2D
b restricted MHC class I peptide. Specific lysis was determined at effector:target ratios of 60:1, 20:1 and 7:1 in a standard
51Cr-
release assay. Cut-off for a positive lysis has been set to 20% specific lysis. In vivo clearance of transient hepatic NS3/4A-protein expression was
analysed by immunoprecipitation and western blot 72 h after the hydrodynamic injection. ‘‘M’’ indicates the molecular rainbow marker. ‘‘+’’, positive
control (eg, coNS3/4A transiently transfected baby hamster kidney-21 (BHK) cells). The number of NS3-protein positive mice per group is indicated in
the row below each gel. p Values indicate a statistical difference (p,0.05 or p,0.01) between naive and vaccinated mice as determined by Fisher’s
exact test (Statview). In the second row below the gel, the mean number of detectable infiltrating CD3+ T cells/10 mm
2 in the livers of groups of mice
has been given. p Values indicate a statistical difference (p,0.05 or p,0.01) between naive and vaccinated mice as determined by the Mann–Whitney
U test (Statview). Experiments that had been run previously (wild-type, CD42/2, CD82/2 and IFNcR22/2) were run once with five mice per group,
whereas the other experiments were run with a higher number of animals per group (n=6–9). Since results were consistent the latter were only run once.
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FasL2/2 mice failed to develop lytic T cells that were
detectable in vitro, although IFNc-producing cells were recalled
in vitro confirming that T cells had been primed (fig 4F,G). Also,
the vaccinated perforin2/2 mice had an increased frequency of
CD3+ cells in the liver (fig 4F), suggesting that the absence of
perforin affects killing rather than hepatic trafficking of T cells.
Importantly, these data also suggest that NS3/4A does not
actively interfere with killing mechanisms exerted by perforin
and Fas. In conclusion, using transiently NS3/4A Tg mice with
hepatic NS3/4A expression at levels comparable to humans, we
found no apparent role for NS3/4A to participate in the
observed inhibition of CTL responses observed in HCV-infected
individuals
10 and transgenic mice.
15
DISCUSSION
The underlying mechanisms that help HCV to establish and
maintain a chronic infection in humans are still poorly
understood.
41 14 0 Several mechanisms that seem to promote
viral persistence have been identified in vitro and in animal
studies.
7 41–44 Many HCV proteins seem to interfere with host
cell signalling, where the NS3/4A complex is the best
characterised, so far.
31 92 0 The NS3/4A-mediated cleavage of
IPS-1 has been documented in human and tamarin cells.
34 35
However, there are significant difficulties in studying these
events repeatedly in infected human livers. It is therefore of the
utmost importance to determine if there are other simpler
model systems that may in the same, or in a different way,
represent the in vivo situation. Since a number of transgenic
mouse lineages exist where NS3/4A should be present,
16 17 45 we
studied the effects of NS3/4A in murine cells.
In line with previous reports
31 92 3 we found that over-
expression of NS3/4A in human cells reduced poly(I:C)-induced
IFN and NF-kB activation. One peculiar observation was that
the reported cleavage of Toll-IL1 receptor domain containing
adaptor inducing interferon b (TRIF) found in human cells,
20
could not be documented in murine cells (unpublished
observations) and this cleavage seems to differ between
different human cell lines.
46 The mice with stable transgene
expression of NS3/4A had a lower expression of NS3/4A as
compared to infected humans, whereas the levels in the
transiently NS3/4A Tg mice were somewhat better comparable
to humans. Thus, this suggests that transgenic mouse models
are valid but these differences in expression levels need to be
kept in mind. In addition, when NS3/4A is present in murine
cells it seems to behave similarly as when present in human
cells. This was supported by the observation that the NF-kB
response to poly(I:C) was reduced in murine SP2/0 cells
transiently transfected with NS3/4A. In addition, in poly(I:C)-
treated NS3/4A Tg mouse livers the activation of IRF-3 and NF-
kB was reduced, whereas, as predicted, TNFa failed to do the
same.
33 Thus, the effects seen on IRF-3 and NF-kB after
poly(I:C) treatment were specific for the RIG-I/TLR3-depen-
dent pathway, suggesting that the response to dsRNA was
impaired by NS3/4A also in murine cells. We therefore tested
whether our NS3/4A protein cleaved murine IPS-1. This was
indeed the case as determined by both an in vitro transcription
and translation assay as well as in transiently transfected cells.
Comparison with the efficiency by which mutant NS3/4A
sequences cleaved human IPS-1, suggested that the cleavage of
mouse IPS-1 was less efficient than human IPS-1. Also, this
suggests that different HCV NS3/4A sequences may cleave IPS-
1 with different efficiencies, which certainly merits further
investigation. Thus, it is likely to assume that the NS3/4A-
mediated cleavage of murine IPS-1 is the cause for a reduced
response to dsRNA in vitro and in vivo. This supports the
Figure 4 continued.
Hepatology
Gut 2009;58:560–569. doi:10.1136/gut.2007.147264 567findings from human tumour cells where NS3/4A blocks the
dsRNA-induced interferon response mediated by RIG-I, IPS-1
and IRF-3.
31 92 3 Hence, these signalling events may now be
studied in detail in vivo, albeit with care, using mouse models.
A role for NS3/4A in blocking responses to dsRNA in viral
pathogenesis seems obvious, since this should prevent induction
of an antiviral state and apoptosis of infected cells. However, it
is not known whether this extends to the adaptive immunity.
There are several potential ways in which NS3/4A could inhibit
the adaptive immunity directly or indirectly. For example, the
cleavage of IPS-1 may inhibit chemokine release, hamper the
recruitment of T cells to the liver, or inactivate various immune
targets by blocking MHC class I presentation, or by preventing
Fas or perforin/granzyme mediated killing. If this was indeed
the case, this should be detectable in mouse livers transiently
expressing NS3/4A as an impaired clearance of transfected cells.
We could show that NS3/4A did not promote persistence of a
co-transfected reporter gene by in vivo imaging. Also, we could
show that the clearance of NS3/4A-protein expressing hepato-
cytes followed the classical pattern of lytic elimination requiring
IFNc, perforin and Fas, generally seen in viral infections.
37 38 47
Thus, this strongly suggests that these pathways are not
affected by NS3/4A. This issue was partially addressed also in a
recent study using another RNA virus, the murine lymphocy-
toid choriomeningitis virus,
24 showing that the priming of virus-
specific CTLs by the infecting virus was independent of IPS-1.
Taken together, this suggests that IPS-1 does not seem to be
critical for CTLs either at the priming or the effector stage.
Moreover, these data confirm our previous observation, that the
reported inactivation of the Fas-related molecule Bid seen in
mice that express the full HCV polyprotein,
15 is probably not
mediated by NS3/4A.
17
In conclusion, the inhibition of dsRNA-induced RIG-I
signalling was impaired in vivo in mice with 25-fold lower
expression levels of NS3/4A than those seen in infected human
livers. However, even when using mice with higher expression
levels of NS3/4A, we found no clear evidence for an NS3/4A-
mediated protective effect of ‘‘infected’’ cells towards CTLs.
This is in line with recent studies, using unrelated RNA viruses,
showing that IPS-1 is not required for the adaptive immune
response.
24 25
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Robin Spiller, editor
Right upper quadrant pain and fever
following a fall in a 92 year old
CLINICAL PRESENTATION
A 92-year-old woman presented with a week’s history of right
upper abdominal pain, confusion and a low grade pyrexia.
Preceding the illness, she had stumbled and fallen onto her right
side. Clinical examination revealed tenderness and fullness on
the right side of the abdomen. She was not jaundiced and her
liver function tests were normal.
An abdominal CT demonstrated a cystic structure of
uncertain origin in the right paracolic gutter. MRI showed a
complex layered lesion with a fluid centre extending from the
subhepatic space to the right iliac fossa (figs 1 and 2). The liver
and biliary tree appeared normal. The patient had localised
peritonism and, as the aetiology of her abdominal mass was
unclear, a laparotomy was performed.
QUESTION
What is the nature of this mass and where is it arising from?
See page 612 for answer.
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Figure 2 MR T2 coronal sequence.
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